SARS-CoV-2 variants, spike mutations and immune escape.
SARS-CoV-2 variants, spike mutations and immune escape.
复制标题
DOI：
10.1038/s41579-021-00573-0
复制
发表时间：
2021-07
期刊：
影响因子：
--
通讯作者：
Robertson DL
中科院分区：
文献类型：
--
作者：
Harvey WT;Carabelli AM;Jackson B;Gupta RK;Thomson EC;Harrison EM;Ludden C;Reeve R;Rambaut A;COVID-19 Genomics UK (COG-UK) Consortium;Peacock SJ;Robertson DL
尽管严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）基因组中的大多数突变预计要么是有害的，要么是迅速清除的，要么是相对中性的，但一小部分突变会影响功能特性，并可能改变感染性、疾病严重程度或与宿主免疫的相互作用。SARS-CoV-2在2019年底出现之后，经历了一段持续约11个月的相对进化停滞期。然而，自2020年底以来，SARS-CoV-2进化的特征是出现了一系列突变，这些突变在“令人担忧的变体”的背景下影响了病毒特征，包括传播性和抗原性，这可能是对人类免疫特征变化的反应。有新的证据表明，疫苗接种后血清对某些SARS-CoV-2变体的中和作用降低;然而，需要更好地了解保护的相关性，以评估这可能如何影响疫苗的有效性。尽管如此，制造商正在为可能的疫苗序列更新准备平台，而且至关重要的是，在进行实验以阐明突变的表型影响的同时，还必须监测全球病毒种群的遗传和抗原变化。在这篇综述中，我们总结了关于SARS-CoV-2刺突蛋白（主要抗原）突变的文献，重点是它们对抗原性的影响，并将它们置于蛋白质结构中，并在全球序列数据集中观察到的突变频率的背景下讨论它们。严重急性呼吸道综合征冠状病毒2型（SARS-CoV-2）的演变特征是出现了影响病毒特征（包括传播性和抗原性）的突变和所谓的令人担忧的变体。在这篇综述中，COVID-19 Genomics UK（COG-UK）Consortium的成员及其同事总结了SARS-CoV-2刺突蛋白的突变，重点关注它们对抗原性的影响，并将它们置于蛋白质结构中，并在全球序列数据集中观察到的突变频率的背景下讨论它们。
Although most mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome are expected to be either deleterious and swiftly purged or relatively neutral, a small proportion will affect functional properties and may alter infectivity, disease severity or interactions with host immunity. The emergence of SARS-CoV-2 in late 2019 was followed by a period of relative evolutionary stasis lasting about 11 months. Since late 2020, however, SARS-CoV-2 evolution has been characterized by the emergence of sets of mutations, in the context of ‘variants of concern’, that impact virus characteristics, including transmissibility and antigenicity, probably in response to the changing immune profile of the human population. There is emerging evidence of reduced neutralization of some SARS-CoV-2 variants by postvaccination serum; however, a greater understanding of correlates of protection is required to evaluate how this may impact vaccine effectiveness. Nonetheless, manufacturers are preparing platforms for a possible update of vaccine sequences, and it is crucial that surveillance of genetic and antigenic changes in the global virus population is done alongside experiments to elucidate the phenotypic impacts of mutations. In this Review, we summarize the literature on mutations of the SARS-CoV-2 spike protein, the primary antigen, focusing on their impacts on antigenicity and contextualizing them in the protein structure, and discuss them in the context of observed mutation frequencies in global sequence datasets. The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been characterized by the emergence of mutations and so-called variants of concern that impact virus characteristics, including transmissibility and antigenicity. In this Review, members of the COVID-19 Genomics UK (COG-UK) Consortium and colleagues summarize mutations of the SARS-CoV-2 spike protein, focusing on their impacts on antigenicity and contextualizing them in the protein structure, and discuss them in the context of observed mutation frequencies in global sequence datasets.
登录
查看更多内容
影响因子：
64.8
作者：
Barnes CO;Jette CA;Abernathy ME;Dam KA;Esswein SR;Gristick HB;Malyutin AG;Sharaf NG;Huey-Tubman KE;Lee YE;Robbiani DF;Nussenzweig MC;West AP Jr;Bjorkman PJ
通讯作者：
Bjorkman PJ
SARS-COV-2血统的估计可传播和影响B.1.1.7在英国。
DOI：
10.1126/science.abg3055
发表时间：
2021-04-09
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Davies NG;Abbott S;Barnard RC;Jarvis CI;Kucharski AJ;Munday JD;Pearson CAB;Russell TW;Tully DC;Washburne AD;Wenseleers T;Gimma A;Waites W;Wong KLM;van Zandvoort K;Silverman JD;CMMID COVID-19 Working Group;COVID-19 Genomics UK (COG-UK) Consortium;Diaz-Ordaz K;Keogh R;Eggo RM;Funk S;Jit M;Atkins KE;Edmunds WJ
通讯作者：
Edmunds WJ
DOI：
10.1073/pnas.1108754108
发表时间：
2011-12-20
影响因子：
11.1
作者：
Das, Suman R.;Hensley, Scott E.;Yewdell, Jonathan W.
通讯作者：
Yewdell, Jonathan W.
影响因子：
5.3
作者：
Duchene, Sebastian;Featherstone, Leo;Baele, Guy
通讯作者：
Baele, Guy
影响因子：
64.8
作者：
Collier DA;Ferreira IATM;Kotagiri P;Datir RP;Lim EY;Touizer E;Meng B;Abdullahi A;CITIID-NIHR BioResource COVID-19 Collaboration;Elmer A;Kingston N;Graves B;Le Gresley E;Caputo D;Bergamaschi L;Smith KGC;Bradley JR;Ceron-Gutierrez L;Cortes-Acevedo P;Barcenas-Morales G;Linterman MA;McCoy LE;Davis C;Thomson E;Lyons PA;McKinney E;Doffinger R;Wills M;Gupta RK
通讯作者：
Gupta RK